Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/1/2024 | Overweight → Equal-Weight | Morgan Stanley | |
7/8/2024 | $19.00 | Overweight | Barclays |
2/9/2024 | $26.00 | Overweight | Wells Fargo |
12/19/2023 | $16.00 → $18.00 | Buy | Needham |
10/20/2023 | $22.00 | Buy | ROTH MKM |
10/12/2022 | $12.00 | Buy | Jefferies |
9/12/2022 | $13.00 | Overweight | Morgan Stanley |
3/2/2022 | $22.00 → $17.00 | Overweight | Piper Sandler |
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2024 financial results on October 30, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Indu
Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report second quarter 2024 financial results on July 31, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months.
Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report first quarter 2024 financial results on May 7, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. In
Morgan Stanley downgraded Alphatec from Overweight to Equal-Weight
Barclays initiated coverage of Alphatec with a rating of Overweight and set a new price target of $19.00
Wells Fargo initiated coverage of Alphatec with a rating of Overweight and set a new price target of $26.00
Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor conferences: The Stifel Healthcare Conference at the Lotte New York Palace Hotel in New York, NY, on November 18, 2024, with a fireside chat at 3:35pm ET The Jefferies London Healthcare Conference at the Waldorf Hilton in Aldwych, London, on November 20, 2024, with a fireside chat at 9:30am GT The Piper Sandler Healthcare Conference at the Lotte New York Palace Hotel in New York, NY, on December 4, 2024, with a fireside chat at 2:30pm ET The Stifel MedTech Madness West Coast Bu
Surgical revenue grew 30%; total revenue grew 27% Full-year revenue and profitability guidance increased Enhanced balance sheet flexibility with $50 million expansion of existing term loan facility Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended September 30, 2024, and recent corporate highlights. Third Quarter 2024 Financial Results Quarter Ended September 30, 2024 Total revenue $151 million GAAP gross margin 68% Non-GAAP gross margin 69% GAAP operating expenses $136 million Non-GAAP operating expe
Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2024 financial results on October 30, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Indu
144 - Alphatec Holdings, Inc. (0001350653) (Subject)
S-3ASR - Alphatec Holdings, Inc. (0001350653) (Filer)
10-Q - Alphatec Holdings, Inc. (0001350653) (Filer)
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
4 - Alphatec Holdings, Inc. (0001350653) (Issuer)
SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)
SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)
SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)
Canaccord Genuity analyst Caitlin Cronin maintains Alphatec Holdings (NASDAQ:ATEC) with a Buy and maintains $25 price target.
Across the recent three months, 4 analysts have shared their insights on Alphatec Holdings (NASDAQ:ATEC), expressing a variety of opinions spanning from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Alphatec Holdings, presenting an average target of $18.
Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri
Brian Snider Appointed New CEO Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today that John Booth will retire from his role as Chief Executive Officer of Spineology, effective November 10, 2023. The Board of Directors has selected Brian Snider as its next Chief Executive Officer, effective November 13, 2023. Mr. Booth will remain with Spineology through 2024, serving in an advisory role to facilitate a smooth transition. Mr. Booth will also resign from the Board of Directors, and the Board has nominated Mr. Snider as a Director. Snider joins Spineology with nearly twenty years of progressive leadership experience in the
Enhances EOS platform with automated alignment, surgical planning, patient-specific rod-bending, and intra-operative alignment reconciliation capabilities Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that EOS Catalyst will be introduced at the 2023 NASS Annual Meeting. EOS Catalyst builds on the already unprecedented functionality of the EOS imaging platform with automated alignment and surgical planning capabilities. "EOS is foundational to ATEC's mission to revolutionize spine surgery," said Pat Miles, Chairman and Chief Executive Officer. "Catalyst will be the first reflection of